Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 4, 2017, Pages 509-516

  Petrie, John R ^a,j   Chaturvedi, Nish ^b   Ford, Ian ^a,j   Hramiak, Irene ^c   Hughes, Alun D ^a,j   Jenkins, Alicia J ^d,j   E Klein, Barbara ^e   Klein, Ron ^e   Ooi, Teik Chye ^f   Rossing, Peter ^g   Sattar, N ^j   Stehouwer, Coen D A ^h   Colhoun, Helen M ⁱ   Kean, S ^j,j   Thomson, E ^j   Gillespie, L ^j,j   Gibb, J ^j   Greenlaw, N ^j   Hramiak, I ^j   Keech, A ^j   Chaturvedi, N ^j   March, K ^j   Coady, E ^j   Tillin, T ^j   Bots, M ^j   Klein, R ^j   Klein, B ^j   Dreyer, J ^j   Jan, T ^j   Meuer, S ^j   Murach, D ^j   Sheffy, Koby ^j   Lusky, Ravit ^j   Peleg, S ^j   Colhoun, H ^j   Shore, A ^j   Carty, D ^j   Donnan, P ^j   Witham, M ^j   Adler, A ^j   Lonn, E ^j   Rauchhaus, P ^j   Lindsay, R ^j   Brouwers, M ^j   Van Melckebeke, J ^j   Hamill, T ^j   Cuthbertson, L ^j   Murray, A ^j   Jolly, L ^j   Miller, E ^j   Hair, J ^j   Bell, A ^j   Carmichael, S ^j   Douglas, E ^j   Surtees, P ^j   Dinnett, E ^j   Allan, J ^j   Watson, C ^j   McLaughlin, M ^j   Brindley, G ^j   Smillie, E ^j   Motherwell, D ^j   MacDonald, S ^j   Ellis, P ^j   Stuart, D ^j   Travers, M ^j   Brearley, S ^j   Greig, L ^j   Haw, J ^j   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g STENO DIABETES CENTER   (Denmark)

^h MAASTRICHT UNIVERSITY   (Netherlands)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j NONE

more..

Author keywords

adjunct therapy; cardiovascular; carotid intima media thickness; clinical trial; complications; endothelial function; hypoglycaemia metformin; type 1 diabetes; weight

Indexed keywords

BIGUANIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECHOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; RISK FACTOR; SINGLE BLIND PROCEDURE; STEADY STATE; WEIGHT GAIN; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOLOGY;

ADULT; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY WEIGHT; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; RISK FACTORS; SINGLE-BLIND METHOD;

EID: 85013412151     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12840     Document Type: Article

References (49)

1. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9:e1001321.
2. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network Epidemiology Group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313:37-44.
3. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39:686-693.
4. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32:1036-1050.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
6. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA. 1998;280:140-146.
7. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56:1162-1170.
8. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398-404.
9. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med. 2013;30:179-188.
10. Vella S, Buetow L, Royle P, Livingstone S, Colhoun H, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53:809-820.
11. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008;3:e3363:1-12.
12. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11:966-977.
13. Libman IM, Miller KM, DiMeglio LA, et al.; T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314:2241-2250.
14. U.K. Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
15. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616-625.
16. Holden SE, Jenkins-Jones S, Currie CJ. Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One. 2016;11:e0153594.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429-442.
18. Nathan DM, Lachin J, Cleary P, et al.; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
19. Wendelhag I, Liang Q, Gustavsson T, Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke. 1997;28:2195-2200.
20. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(suppl 5):786-806.
21. Palombo C, Kozakova M, Morizzo C, et al. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol. 2011;10:88.
22. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers; 1994:111-132.
23. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies design options, progression rates, and sample size considerations. Stroke. 2003;34:2985-2994.
24. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;5:1422-1431.
25. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059-4067.
26. Zhou G, Myers R, Li Y, et al. Role of AMP activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
27. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542-546.
28. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198-205.
29. Jadhav ST, Ferrell WR, Petrie JR, Greer I, Cobbe SM, Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006;48:956-963.
30. Almabrouk TA, Ewart MA, Salt IP, Kennedy S. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol. 2014;171:595-617.
31. Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64:2028-2041.
32. Beisswenger PJ. Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications. Biochem Soc Trans. 2014;42:450-456.
33. Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:116-124.
34. Lundby-Christensen L, Tarnow L, Boesgaard TW, et al. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open. 2016;6:e008376.
35. Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008;35:895-903.
36. Matsumoto K, Gera Y, Abe Y, Tominanga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract. 2004;64:225-228.
37. Djaberi R, Schuijf JD, Boersma E, et al. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography. Diabetes Care. 2009;32:1507-1512.
38. Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12:156.
39. Haute Autorité Santé. Commission de la transparence: Avis 5 septembre 2012. http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_1298703. Accessed July 19, 2016.
40. National Institute for Health and Care Excellence. (August 2015, updated November 2015). Type 1 diabetes in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng17?unlid=43059219201639184149. Accessed July 19, 2016.
41. Faichney JD, Tate PW. Metformin in type 1 diabetes: is this a good or bad idea? Diabetes Care. 2003;26:1655.
42. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B12 deficiency: randomised, placebo controlled trial. BMJ. 2010;340:c2181. doi: 10.1136/bmj.c2181.
43. Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B(12) deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2016;42(5):316-327.
44. Lorenz MW, Price JF, Robertson C, et al. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. Diabetes Care. 2015;38:1921-1929.
45. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008-2017.
46. Collins R, Armitage J, Parish S, Sleigh P, Peto R Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
47. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
48. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
49. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;26(373):2117-2128.